Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PAR-24-049: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Closed Closed January 7, 2025 Opportunity PAR-24-049

This grant is closed. A newer notice from the same program is open now: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) (PAR-25-032). Status: Due dates in the notice, expires March 16, 2027. It is in our archive of National Institutes of Health notices from 2023.

National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2025.

From the official notice on Grants.gov, last changed December 18, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under PAR-24-049 were run by National Heart Lung and Blood Institute (NHLBI, 14 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read PAR-24-049 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-25-032December 18, 2024Due dates in the notice, expires March 16, 2027Open

Key dates

PostedNovember 3, 2023
DeadlineJanuary 7, 2025
Archived by Grants.govFebruary 6, 2025

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Category: Health.

Funded under PAR-24-049 so far

NIH funded 14 projects under PAR-24-049 in fiscal 2025 to 2026, at 13 institutions. The median yearly award was $322,310.

Most projects: University of California, San Francisco (California), 2, Medical University of South Carolina (South Carolina), 1, Icahn School of Medicine at Mount Sinai (New York), 1, George Washington University (District of Columbia), 1, Cleveland Clinic Lerner Com-Cwru (Ohio), 1.

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cardiovascular Diseases Research grants before

From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Trustees of the University of PennsylvaniaPennsylvania313$380 million
Brigham & Womens Hospital IncMassachusetts274$374 million
Regents of the University of MichiganMichigan277$355 million
The Trustees of Columbia University in the City of New YorkNew York207$335 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania295$320 million

Top states: California ($1.8 billion), Massachusetts ($1.5 billion), New York ($1.4 billion), Pennsylvania ($1.1 billion), Ohio ($749 million).

Who has won Lung Diseases Research grants before

From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The General Hospital CorporationMassachusetts1$5.4 million
New England Research Institutes IncMassachusetts1$2.7 million
The Trustees of the University of PennsylvaniaPennsylvania1$355,699
University of WashingtonWashington1$350,272
The Trustees of Columbia University in the City of New YorkNew York1$319,659

Top states: Massachusetts ($7.8 million), Washington ($350,272), New York ($319,659), Pennsylvania ($300,836).

Who has won Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders grants before

From fiscal 2021 to 2025, Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (93.840) awarded $3.3 million across 9 grant awards, an average of $364,164 per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Regents of the University of ColoradoColorado1$1.5 million
Indiana Department of HealthIndiana1$558,986
Minnesota Department of HealthMinnesota1$442,754
Michigan Public Health InstituteMichigan1$311,837
City of PhiladelphiaPennsylvania1$251,231

Top states: Colorado ($1.5 million), Indiana ($558,986), Minnesota ($442,754), Michigan ($311,837), South Carolina ($191,177).

Applying now

This notice no longer takes applications. Apply under the newer notice, PAR-25-032, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PAR-24-049 still open?

No. It closed on January 7, 2025. A newer notice is open: PAR-25-032, due dates in the notice, expires March 16, 2027.

Who can apply for NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)?

Closed January 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has been funded under PAR-24-049?

NIH RePORTER lists 14 projects funded under PAR-24-049 in fiscal 2025 to 2026, at 13 institutions. The most were at University of California, San Francisco, Medical University of South Carolina, Icahn School of Medicine at Mount Sinai.

Who has won Cardiovascular Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.

Similar open grants